Back then, it wasn't unreasonable to suspect that
Post# of 148288
(Total Views: 538)
Posted On: 10/28/2020 4:43:31 PM
Back then, it wasn't unreasonable to suspect that targeting an immune cell surface receptor with an engineered MAB would be playing with fire and likely pave a road to hell for patients receiving the novel treatment.
Precisely how Leronlimab avoids any harmful side effects while occupying one of these receptors is something I hope we learn much more about in the future.
Precisely how Leronlimab avoids any harmful side effects while occupying one of these receptors is something I hope we learn much more about in the future.
(1)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼